A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma

被引:30
|
作者
Hernandez-Alejandro, Roberto [1 ]
Croome, Kris P. [1 ]
Drage, Martin [1 ]
Sela, Nathalie [1 ]
Parfitt, Jeremy [2 ]
Chandok, Natasha [1 ]
Marotta, Paul [1 ]
Dale, Cheryl [1 ]
Wall, William [1 ]
Quan, Douglas [1 ]
机构
[1] London Hlth Sci Ctr, Dept Surg, Multiorgan Transplant Program, London, ON N6A 5A5, Canada
[2] London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada
基金
英国医学研究理事会;
关键词
Hepatitis C virus; Liver transplant; Hepatocellular carcinoma; Non-alcoholic steatohepatitis; Comparison; Recurrence; Vascular invasion; Poorly differentiated; Survival; FATTY LIVER-DISEASE; CRYPTOGENIC CIRRHOSIS; NATURAL-HISTORY; UNITED-STATES; TRANSPLANTATION; RECURRENCE; NASH; FREQUENCY;
D O I
10.3748/wjg.v18.i31.4145
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To compare the clinical outcome and pathologic features of non-alcoholic steatohepatitis (NASH) patients with hepatocellular carcinoma (HCC) and hepatitic C virus (HCV) patients with HCC (another group in which HCC is commonly seen) undergoing liver transplantation. METHODS: Patients transplanted for HCV and NASH at our institution from January 2000 to April 2011 were analyzed. All explanted liver histology and pre-transplant liver biopsies were examined by two specialist liver histopathologists. Patient demographics, disease free survival, explant liver characteristics and HCC features (tumour number, cumulative tumour size, vascular invasion and differentiation) were compared between HCV and NASH liver transplant recipients. RESULTS: A total of 102 patients with NASH and 283 patients with HCV were transplanted. The incidence of HCC in NASH transplant recipients was 16.7% (17/102). The incidence of HCC in HCV transplant recipients was 22.6% (64/283). Patients with NASH-HCC were statistically older than HCV-HCC patients (P < 0.001). A significantly higher proportion of HCV-HCC patients had vascular invasion (23.4% vs 6.4%, P = 0.002) and poorly differentiated HCC (4.7% vs 0%, P < 0.001) compared to the NASH-HCC group. A trend of poorer recurrence free survival at 5 years was seen in HCV-HCC patients compared to NASH-HCC who underwent a Liver transplantation (P = 0.11). CONCLUSION: Patients transplanted for NASH-HCC appear to have less aggressive tumour features compared to those with HCV-HCC, which likely in part accounts for their improved recurrence free survival. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:4145 / 4149
页数:5
相关论文
共 50 条
  • [31] Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: Implications for Lycopene Intervention
    Ip, Blanche C.
    Wang, Xiang-Dong
    NUTRIENTS, 2014, 6 (01) : 124 - 162
  • [32] Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma
    Yasui, Kohichiroh
    Hashimoto, Etsuko
    Tokushige, Katsutoshi
    Koike, Kazuhiko
    Shima, Toshihide
    Kanbara, Yoshihiro
    Saibara, Toshiji
    Uto, Hirofumi
    Takami, Shiro
    Kawanaka, Miwa
    Komorizono, Yasuji
    Okanoue, Takeshi
    HEPATOLOGY RESEARCH, 2012, 42 (08) : 767 - 773
  • [33] Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma
    Tanizaki, H
    Ryu, M
    Kinoshita, T
    Kawano, N
    Konishi, M
    Cho, A
    Nakatsura, T
    Natsume, T
    Takahashi, S
    Sugita, M
    Izuishi, K
    Yoshino, M
    Furuse, J
    Iwasaki, M
    Tsubono, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (02) : 67 - 70
  • [34] Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma
    Green, Christopher D.
    Spiegel, Sarah
    ADVANCES IN BIOLOGICAL REGULATION, 2023, 87
  • [35] Non-invasive Biomarkers in Non-Alcoholic Steatohepatitis-induced Hepatocellular Carcinoma
    Voiculescu, Mihai
    Nanau, Radu M.
    Neuman, Manuela G.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2014, 23 (04) : 425 - 429
  • [36] Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
    Kuo, Joseph
    Serrano, Sonia Simon
    Gronberg, Alvar
    Massoumi, Ramin
    Hansson, Magnus Joakim
    Gallay, Philippe
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [37] Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis
    Castello, Beatriz
    Aguilera, Victoria
    Teresa Blazquez, M.
    Rubin, Angel
    Garcia, Maria
    Vinaixa, Carmen
    Benlloch, Salvador
    SanJuan, Fernando
    Montalva, Eva
    Lopez, Rafael
    Berenguer, Marina
    ANNALS OF HEPATOLOGY, 2019, 18 (06) : 855 - 861
  • [38] Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
    Takakura, Kazuki
    Oikawa, Tsunekazu
    Nakano, Masanori
    Saeki, Chisato
    Torisu, Yuichi
    Kajihara, Mikio
    Saruta, Masayuki
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [39] Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma
    Neuman, Manuela G.
    Cohen, Lawrence B.
    Malnick, Stephen
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 323
  • [40] Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma
    Hye Kyong Park
    Sang Soo Lee
    Chang Bin Im
    Changjo Im
    Ra Ri Cha
    Wan Soo Kim
    Hyun Chin Cho
    Jae Min Lee
    Hyun Jin Kim
    Tae Hyo Kim
    Woon Tae Jung
    Ok-Jae Lee
    BMC Cancer, 19